SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 08/29/2025 at 23:50, 5 months 2 days ago

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia. Novel treatment targets BTK through multi-immune modulation to address root causes of ITP, providing rapid and durable platelet response and improved symptoms

Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia LUNA 3 Study
PRESS RELEASE

published on 08/25/2025 at 18:30, 5 months 6 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 5 months 13 days ago

Sanofi publie le nombre total d'actions et de droits de vote pour juillet 2025

Actions Droit De Vote 2025 Sanofi Code De Commerce Français
BRIEF

published on 08/18/2025 at 18:35, 5 months 13 days ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
PRESS RELEASE

published on 08/18/2025 at 18:30, 5 months 13 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 08/14/2025 at 07:05, 5 months 18 days ago

Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE

Sanofi EMA Médicament Orphelin Rilzabrutinib Maladie IgG4
BRIEF

published on 08/14/2025 at 07:05, 5 months 18 days ago

Sanofi's rilzabrutinib granted orphan drug designation in the EU

Sanofi EMA Orphan Drug Rilzabrutinib IgG4 Disease
PRESS RELEASE

published on 08/14/2025 at 07:00, 5 months 18 days ago

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
Sanofi obtient la désignation de médicament orphelin pour le rilzabrutinib dans l'UE contre la maladie liée aux IgG4. Étude de phase 2 positive présentée à l'EULAR 2025

États-Unis Sanofi Médicament Orphelin Rilzabrutinib Maladie IgG4
PRESS RELEASE

published on 08/14/2025 at 07:00, 5 months 18 days ago

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib granted orphan designation in EU for IgG4-related disease. Positive Phase 2 results presented at EULAR 2025 Congress showcasing efficacy and safety profile

Sanofi Rilzabrutinib Orphan Designation IgG4-related Disease EULAR 2025
PRESS RELEASE

published on 08/11/2025 at 18:30, 5 months 20 days ago

Sanofi: Disclosure of trading in own shares

Published on 01/31/2026 at 03:15, 1 day 8 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 9 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 10 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 11 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 12 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 19 hours 57 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 23 hours 26 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 9 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 13 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 15 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 18:40, 1 day 17 hours ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 1 day 17 hours ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 1 day 18 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 1 day 18 hours ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 2 days 3 hours ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News